- Home
- SNY
SNY
Sanofi ADS
as 10-28-2025 1:48am EST
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
| Founded: | 1994 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 116.1B | IPO Year: | N/A |
| Target Price: | $61.50 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 8.67 | EPS Growth: | 105.93 |
| 52 Week Low/High: | $44.62 - $60.12 | Next Earning Date: | 10-24-2025 |
| Revenue: | $53,890,648,839 | Revenue Growth: | -5.19% |
| Revenue Growth (this year): | 1.4% | Revenue Growth (next year): | 6.67% |
Latest Sanofi ADS News
SNY Breaking Stock News: Dive into SNY Ticker-Specific Updates for Smart Investing
GlobeNewswire
an hour ago
Press release: Sanofi successfully prices USD 3 billion of bond issue
GlobeNewswire
6 hours ago
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
PR Newswire
11 hours ago
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
Morningstar Research
3 days ago
Analyst Report: Sanofi
Investor's Business Daily
3 days ago
Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue
MT Newswires
3 days ago
Sector Update: Health Care Stocks Edge Higher Late Afternoon
GuruFocus.com
4 days ago
Sanofi SA (SNY) Q3 2025 Earnings Call Highlights: Strong Growth Driven by DUPIXENT and New Launches
MT Newswires
4 days ago
Sector Update: Health Care Stocks Advance Friday Afternoon
Compare SNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNY Sanofi ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.